08.00 Registration and refreshments

08.30 Organiserfs welcome remarks 

08.45 Guest-of-honour address 
         Lim Hng Kiang, Minister 
         Ministry of Trade & Industry, Singapore

08.55 Chairman's welcome remarks

09.00  Global keynote address and executive interview: The evolving biomedical 
          science and industry
          • Market trends and drivers of the biomedical industry and crystal balling future growth
          • Emerging biomedical innovation from Asia and its impact 
          • The evolution of the global biotech capital market: Where and how does Asia fit into the 
            equation
         Keynote speakers:    
         Gordon Binder, Managing Director, Coastview Capital, USA
         Founder & former CEO, Amgen Inc, USA         
         Philippe Kourilsky, Chair of Immunology, College de France        
         Former Director General, Pasteur Institute, France    
        Ansbert Gadick, Founder & General Partner, MPM Capital, USA       
         Interviewer:
         Lorraine Hahn, Journalist & TV Presenter, Former TV Talk-show-host & Anchor
         CNN and CNBC, Hong Kong

10.00 Morning refreshments, BioMedical Technology Showcase session & 
         combined 

         Chairman:    
         Muhammad Tani Tabiin, Vice President, Biomedical Sciences Division
         Exploit Technologies Pte Ltd, A* STAR, Singapore

11.00 Welcome & opening remarks    
         Boon Swan Foo, Executive Chairman
         Exploit Technologies Pte Ltd, A*STAR, Singapore 

PARTNERSHIP MODELS FOR SUCCEEDING IN TODAYfS MARKETS - A GLOBAL PERSPECTIVE

11.15  Keynote: The Technology Transfer Network        
          • Introducing the Technology Transfer Network (TTN), a strategic alliance and partnership of 
            technology transfer offices, multinational companies, SMEs, VCs and entrepreneurs
          • Leveraging  on the expertise and resources of a network of technology transfer offices to 
            achieve  greater effectiveness in technology transfer
          • How  this  alliance  will  facilitate cross-border and public-private partnerships  and 
            positively impact on the  growth of companies and the economy 
          Walter Lee, Senior Vice President and Fellow
          Exploit Technologies Pte Ltd,  A*STAR, Singapore

11.40  Keynote: Towards a fully integrated pharmaceutical network: Partnerships in 
          R&D 
          • The challenges of sustaining innovation quality and productivity and the need to evaluate 
             and adapt to new models of R&D
          • The nonlinear acceleration of innovation opportunities through strategic networks
          • Key learning on scaling networks and challenges on both sides
          • Examples and ideas going forward
          Robert Armstrong, Vice President, Global External Research and Development
          Lilly Research Laboratories, USA

12.10  Success in Partnerships: Importance of relationship management through 
          alliance management practices 
          While alliances can hold great promise for the Pharmaceutical and biotechnology industry, 
          their success is threatened if companies don't pay attention to managing the differences in 
          pre-existing corporate cultures, organizational structures and decision making processes. 
          Alliance Management best practices will help address the below and instituting these 
          practices in all partnerships will help achieve trust and maximize value for all parties 
          involved in the alliance.
          • Organizational dynamics
          • Communication
          • Governance
          • Process
          Varavani Dwarki, Vice President, Alliance Management, Global Business Development
          Wyeth Pharmaceuticals, USA

PRIVATE- PUBLIC PARTNERSHIPS

12.35  How public and private sector can jointly foster innovation for neglected 
          diseases         
          • What are PDP (product development partnerships)
          • DNDi business model: the virtue of being virtual
          • IP rights vs access rights: managing potential conflicts
          • Artesunate-Amodiaquine combination: an example of PDP's success
         Jean-Pierre Paccaud, Director, Business Development
          Drugs for Neglected Diseases Initiative (DNDi), Switzerland

13.00  Networking luncheon & showcase session

REGIONAL PARTNERING AND LICENSING ISSUES & OPPORTUNITIES

14.00  Accessing the Asia pharma market through strategic partnerships  
          • Options to maximise the value of products in Asia through commercial and development 
             licensing
          • The increasing trend of regional and local in-licensing in Asia
          • Some examples of innovative partnerships for bringing new therapies to Asian markets
          Sridhar Gopal, Regional Business Development and Strategic Planning Director, Asia-
          Pacific, AstraZeneca, Singapore

14.30  Case Study: Licensing & risk sharing partnerships as drivers for growth for 
          Indian pharma: Ranbaxy example
          • Emphasising the need for licensing and partnership to accelerate the development of NCEs 
            and biologics for the Indian and global market
          • What are the main licensing and partnership opportunities with Indian companies
          • Risk sharing as an evolving drug development business model in India
          • Examples of Ranbaxy's successful licensing and R&D alliances
          Shyam Bishen, Vice President, Corporate Development
          Ranbaxy Inc., USA

15.00  Case study: The partnering landscape in China and how GSK is leveraging on the 
          China advantage     
          • Licensing and partnering opportunities with Chinese companies and how to tap into this  
            valuable resource
          • How the changes to US-FDAfs rulings and the improved SFDA submission approval   
             times have positively affected the licensing activity/ partnering between 
             multinational pharmas with Chinese companies  
          • How does GSK view China and some of the interesting partnerships happening in   
            China
          Steve Tan, Director, Scientific Collaborations and Business Development
          GlaxoSmithKline R&D, China

15.30  Afternoon refreshments, showcase session &

16.30  Panel Discussion: Evolving pharma-biotech licensing models and trends – The 
          Asia-Pacific perspective     
          • Private-public partnership – How important are these for the survival of the industry in 
            Asia and what are the major difference compared to PPP in US and EU?
          • How can the multinationals  harness the IP and technologies and talent from Asia in a 
            commercial viable way and what do they view as the main strengths the Asia-Pacific IP 
            portfolio?
          • How important are early-stage deal structures to the sustained survival of flourishing 
             biotech industry in Asia ?
          • Cross-border licensing – What are the issues faced in East-West and Inter-Asian deal 
             making – Is this a growing upwards trend and which biomedical sectors and countries in 
             Asia-Pacific are most active
          Moderator:        
          Alex  H.C. Yu, Director, Innovation & Technology  Transfer Office (ITTO)
          Nanyang Technological University (NTU), Singapore &
          Singapore & Immediate Past President
          Licensing Executives Society (Singapore)       
          Panelists: 
          Suresh Sachi, General Counsel
          A*STAR & Past President, LES (Singapore) 
          Guy Heathers, Chief Business Officer
          Cancer Therapeutics CRC, Australia      
          Fred M. Schwarzer, Managing Partner
          Charter Life Sciences, USA 
          Ajan Reginald, Global Head Emerging Technologies, Roche Group Research
          F. Hoffmann-La Roche, Switzerland    
          Sandeep Rao, General Manager, Business Development
          Biocon Ltd, India

17.15  Chairmanfs closing remarks

17.30  Close of day one

19.00  Biomedical Industry Awards & Gala Dinner 

08.30  Registration and refreshments

08.45  Chairmanfs opening remarks

PARTNERING NEEDS OF THE GLOBAL PHARMA AND BIOTECH INDUSTRIES

09.00 Presentations from key global pharmas and biotechs   
         In the proceeding 12 min presentations, representatives from companies with existing 
         partnerships in Asia or actively seeking to establish new partnerships in Asia will highlight the 
         strengths of their company, product focus areas and provide information about partnerships, 
         existing or sought.
         Liz Jazwinska, Executive Director, New Business & Strategic Alliances
         Johnson & Johnson Research Pty Limited, Australia     
         Isato Ohmine, Leader, Licensing Group, Japan/East Asia
         Nippon Boehringer Ingelheim Co. Ltd., Japan 
         Michael Schroter, Chief Operating Officer and Director of Business Development and 
         Alliance Management, Lilly Singapore Centre for Drug Discovery, Singapore         
         Bruce Halpryn, Senior Director, New Business Development, Technical & IP Due Diligence, 
         IP Management, Procter & Gamble Pharmaceuticals, Inc., USA       
         R. Christopher Seaton, Senior Vice President Global Transactions
         Bayer HealthCare Pharmaceuticals, USA 
         Alex Fowkes, Executive Director, Head of Strategic Alliances, Asia
         Pfizer Global Research & Development, China       
         Joe McCracken, Vice President, Business Development
         Genentech Inc., USA

10.30  Morning refreshment & showcase session

11.00  gSpotlight on big pharmah  interview session       
           Licensing executives from global pharmas and biotechs in the above session will be asked 
           for their views on some of  the questions on everyonefs mind by our expert interviewer in 
           a  gtalk showh like fashion
           • What are big pharma looking for and what do they foresee in the future of deal-making in 
              Asia?
           • What are some of the interesting licensing approaches used to harness Asiafs wealth of 
             innovation and talent?
           • What are Asiafs strengths and weakness when it comes to partnerships and licensing?
           • How can Asian companies seeking licensing partners make their products and 
              technologies more attractive for the big pharmas?
           Interviewer:       
           Fintan Walton, Chairman, Chief Executive Officer and Founder
           PharmaVentures, UK    

KEY LICENSING & DEAL-MAKING CASE STUDIES

Exemplary case studies from companies in the Asia-Pacific region who will discuss their  licensing partnerships and strategic alliances related to development of new therapeutics, broaden to include co-development of companion diagnostics/ theranostics and  drug delivery systems.

11.45  Case Study: A novel approach to growth in Asia: The Roche and Chugai 
          Alliance 
          • Building value through partnership - how Roche and Chugai have realized benefits from 
             their collaboration
          • Leveraging innovation on a worldwide basis - using the strengths of both companies to 
             deliver differentiated medicines in areas of high unmet need
          • Structures, Processes, and People - using the right approach to meet local needs while 
             utilizing global resources
          • Success in Asia and beyond - a look at how the Roche – Chugai partnership has 
            established a leadership role in Asia, as well as in the broader global market
          Mark Noguchi, Japan Representative and General Manager
          Roche Pharma Japan   
          Kimio Nishimura, General Manager, Business Development
          Chugai Pharmaceutical Co. Ltd, Japan 

12.15  Case study: Can an Asian biotech company reduce its product development risk 
          by in-licensing clinical stage drug candidates?         
          • Challenges in selecting appropriate clinical stage new drug candidates to in-license and 
            complement its own in-house research program
          • In-licensing challenges for biotech companies in Asia
          • The challenges and success in establishing worldwide development program with multi-
             national collaboration
          • Clinical program in Asia attracts multinational pharmaceuticals and investors' attention
          Stephen Ip, Senior Vice President,  Global Business Development 
          TaiGen Biotechnology Co. Ltd., Taiwan

12.40  Networking luncheon & showcase session

14.00  Case study: How a small Australian biotech company attracted a big 
          pharmaceutical company  
          • Expanding on pSividafs up to $165m licensing agreement with Pfizer
          • The global drug delivery market for ophthalmic applications
          • Importance of multiple drug delivery platforms for securing licensing agreements
          • Importance of US profile for Australasian companies
          Brian Leedman, Vice President
          pSivida Limited, Australia 

14.30  Case study: Formation of late stage biopharmaceutical company Artisan through 
          a unique Japan-US partnership
          • Formation of Artisan, a biopharmaceutical company in the US, by Asahi Kasei Pharma 
             (AKP), Japan, and international investors to develop a late-stage product originated by 
             AKP and other late-stage acute care products
          • Drivers for a Japanese company to form a start-up company funded by venture capitals to 
             develop its product worldwide
          • International development of recombinant human soluble thrombomodulin (ART-123), 
            Artisanfs lead product in Phase 2b stage
          • Manufacturing collaboration in Asia by A-Bio (Singapore), AKP (Japan) and Artisan(US)      
          Hajimu Sakamoto, Vice President, Business Development
          Artisan Pharma, USA 

15.00  Afternoon refreshments &  showcase session

15.30  Small group interactive roundtable discussion    
          A) Partnerships between private and public sectors and the unique hurdles encountered in 
              Asia Pacific
          Moderator:  
          Heidi Meisenkothen, Assistant Vice President, Biomedical Sciences Division
          Exploit Technologies Pte Ltd, A*STAR, Singapore

          B) Exploring new partnering models which enable public healthcare & unmet medical needs 
              in Asia to be addressed 
          Moderator:  
          Anant G. Wadkar, Associate Director, Corporate Development & Strategic Planning
          Dr. Reddy's Laboratories Limited, India 

          C) Trends in early stage biotech deal and the innovative deal structures which help to 
              mitigate risk
          Moderator:      
          Judith Hills, Vice President Licensing (Europe, Japan & Asia Pacific)
          Bristol-Myers Squibb Company, UK

          D) Partnering deals which morph into a take over / M&A – the good, the bad and the 
              necessary 
         Moderator:         
         Chris Molly, Chief Operating Officer
         MerLion Pharmaceuticals, Singapore

         E) Growing Asian bioventures -  A time and place to license, seek investor(s) or be acquired- 
             What are some of the key deciding factors
         Moderator:    
         Marvin Ng, Director
         DN Venture Partners, Singapore

17.00  Chairmanfs closing remarks

17.15  Close of conference